ELCC 2019

0:48
The LUNAR study: TTFields for treating NSCLC
Ori Farber
0:55
TTFields as an anti-mitotic therapy
Ori Farber
2:03
The STELLAR study: TTFields for malignant pleural mesothelioma
Ori Farber
1:35
Afatinib for advanced EGFRm-positive NSCLC
Antonio Passaro
2:03
TKIs to treat EGFRm-positive NSCLC
Marina Garassino
1:16
The promise of stereotactic radiotherapy for oligometastases
Françoise Mornex
1:50
Prof. Kelly’s overview of the RECaN project
Daniel Kelly
2:05
Updates from the PROFILE 1001 study
Alice Tsang Shaw
1:50
The evolving role of the nurse in cancer therapy
Celia Diez de los Rios
1:03
Managing oligometastatic NSCLC with thoracic irradiation
Françoise Mornex
0:42
Second-generation ALK inhibitors in ALK-positive NSCLC
Antonio Passaro
1:42
Recent developments in radiotherapy for lung cancer
Françoise Mornex
0:44
ALK-TKIs: targeted therapies for ALK-positive NSCLC
Antonio Passaro
1:47
Challenges in using ALK inhibitors
Nicolas Girard
1:14
Treatment sequecing strategies in advanced NSCLC
Martin Reck
1:07
PACIFIC trial updates: durvalumab after chemotherapy in NSCLC
Marina Garassino
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals